Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17775029 | 0.90 | FGF1 (0.31) | FGF1OGA | |
| SCHEMBL25594519 | 0.90 | FGF1 (0.31) | FGF1OGA | |
| SCHEMBL19431871 | 0.90 | FGF1 (0.31) | FGF1OGA | |
| SCHEMBL25594513 | 0.90 | FGF1 (0.31) | FGF1OGA | |
| SCHEMBL12769068 | 0.90 | FGF1 (0.31) | FGF1OGA | |
| SCHEMBL19227509 | 0.90 | OGA (0.34) | FGF1OGA | |
| SCHEMBL15907822 | 0.89 | OGA (0.36) | FGF1OGA | |
| SCHEMBL18755379 | 0.85 | OGA (0.33) | FGF1OGA | |
| SCHEMBL19051014 | 0.84 | FGF1 (0.33) | FGF1 | |
| SCHEMBL18294595 | 0.84 | FGF1 (0.33) | FGF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230235076-A1 | HUMANIZED ANTIBODIES AGAINST LEWIS Y | PENTIXAPHARM AG (DE) | 2023-07-27 | — | — | US | disclosed |
| US-9334335-B2 | Surface layer | XEROX CORPORATION (US) | 2016-05-10 | — | — | US | disclosed |
| US-9334335-B2 | Surface layer | XEROX CORPORATION (US) | 2016-05-10 | — | — | US | disclosed |
| US-20140154502-A1 | SURFACE LAYER | XEROX CORPORATION (US) | 2014-06-05 | — | — | US | disclosed |
| US-20140154502-A1 | SURFACE LAYER | XEROX CORPORATION (US) | 2014-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230235076-A1 | HUMANIZED ANTIBODIES AGAINST LEWIS Y | FCGR2A, FCGR3B, CD47 | FGF1 4141/4885OGA 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.